menopause and semaglutide novonordisk Novo Nordisk announced data demonstrating that Wegovy® ( 2.4 mg 7.2 mg) delivers substantial and consistent weight-loss results for women with obesity across reproductive life stages, from premenopausal years through Semaglutide Alternatives That Support Weight

As a company, we believe its important to acknowledge that GLP-1 use is not always continuous and create the programs and protocols to support patients across their entire health journey. Everything that comes fast, goes fast A few years after Calibrates launch, the company itself began collecting data on what happens when customers stop taking the medications

Studies and patient reports show: Rapid weight regain, sometimes more than what was lost Hunger hormones (like ghrelin) return to pre-medication levels Slower metabolism due to muscle loss during rapid weight loss In many cases, doctors recommend indefinite use to maintain results

Most are manageable, especially when treatment starts at a low dose and builds up gradually

Has exercise frequency declined

Tesamorelin can elevate IGF-1 into supraphysiologic ranges and increase fasting glucose or impair insulin sensitivity in some users